The aim of the present study was to investigate the effects of a Rhodiola
rosea L. extract on the prevention of the development of nicotine
dependence and for the reduction of abstinence suffering following nicotine
cessation in mice. Dependence was induced in mice by subcutaneous injections of
nicotine (2 mg/kg, 4 times/day) for eight days. Spontaneous abstinence
syndrome was evaluated 20 h after the last nicotine administration, by analysis
of withdrawal signs, as affective (anxiety-like behaviour) and physical (somatic
signs and locomotor activity). Rhodiola rosea L. extract was
administered orally during nicotine treatment (10, 15 and 20 mg/kg) or
during nicotine withdrawal (20 mg/kg). Results show that both affective
and somatic signs (head shaking, paw tremors, body tremors, ptosis, jumping,
piloerection and chewing) induced by nicotine withdrawal are abolished by
administration of Rhodiola rosea L. extract in a dose-dependent
fashion, during both nicotine exposure and nicotine cessation. In conclusion,
our data encourage additional studies to define the use of R.
rosea L. as a therapeutic approach in the treatment of smoking
cessation.
AbidovMCrendalFGrachevSSeifullaRZiegenfussT (2003) Effect of extracts
from Rhodiola rosea and Rhodiola crenulata
(Crassulaceae) roots on ATP content in mitochondria of skeletal
muscles. B Exp Biol Med136:
585–587.
2.
BalfourDJ (2009) The neuronal
pathways mediating the behavioral and addictive properties of
nicotine. Handb Exp Pharmacol192:
209–233.
3.
BarikJWonnacottS (2009) Molecular and
cellular mechanisms of action of nicotine in the CNS.
Handb Exp Pharmacol192:
173–207.
4.
BenowitzNL (2009) Pharmacology of
nicotine: addiction, smoking-induced disease, and
therapeutics. Annu Rev Pharmacol49:
57–71.
5.
BialaGWeglinskaB (2005) Blockade of the
expression of mecamylamine-precipitated nicotine withdrawal by calcium
channels antagonists. Pharmacol Res51:
483–488.
BrownRPGerbargPLRamazanovZ (2002) Rhodiola
rosea. A phytomedicinal overview.
HerbalGram56:
40–52.
8.
BuchhalterARFantRVHenningfieldJE (2008) Novel
pharmacological approaches for treating tobacco dependence and withdrawal:
current status. Drugs68:
1067–1088.
CartonSLe HouezecJLagrueGJouventR (2002) Early emotional
disturbances during nicotine patch therapy in subjects with and without a
history of depression. J Affect Disorders72:
195–199.
ChenQGZengYSQuZQ (2009) The effects of Rhodiola
rosea extract on 5-HT level, cell proliferation and quantity of
neurons at cerebral hippocampus of depressive rats.
Phytomedicine.
doi:10.1016/j.phymed.2009.03.011.
13.
CohenCPerraultGGriebelGSoubriéP (2005)
Nicotine-associated cues maintain nicotine-seeking behavior
in rats several weeks after nicotine withdrawal: reversal by the cannabinoid
(CB1) receptor antagonist, rimonabant (SR141716).
Neuropsychopharmacology30:
145–155.
14.
CorrigallWA (1999) Nicotine
self-administration in animals as a dependence model.
Nicotine Tob Res1:
11–20.
15.
CrawleyJGoodwinFK (1980) Preliminary report
of a simple animal behavior model for the anxiolytic effects of
benzodiazepines. Pharmacol Biochem Be13:
167–170.
De BiasiMSalasR (2008) Influence of
neuronal nicotinic receptors over nicotine addiction and
withdrawal. Exp Biol Med (Maywood)233:
917–929.
18.
DhawanKKumarSSharmaA (2002) Nicotine reversal
effects of the benzoflavone moiety from Passiflora incarnata Linneaus in
mice. Addict Biol7:
435–441.
19.
DierkerLCAvenevoliSStolarMMerikangasKR (2002) Smoking and
depression: an examination of mechanisms of comorbidity.
Am J Psychiat159:
947–953.
20.
FagerströmKHughesJ (2008) Varenicline in the
treatment of tobacco dependence. Neuropsychiatr Dis
Treat4:
353–363.
21.
FioreMCJae’nCRBakerTB (2008) Treating
tobacco use and dependence: 2008 update U.S. Public Health Service Clinical
Practice Guideline executive summary. 2008 PHS Guideline Update Panel,
Liaisons, and Staff. Respir Care53:
1217–1222.
22.
FowlerJSLoganJWangGJVolkowND (2003) Monoamine oxidase
and cigarette smoking. Neurotoxicology24:
75–82.
23.
GalantiLM (2008) Tobacco smoking
cessation management: integrating varenicline in current
practice. Vasc Health Risk Manag4:
837–845.
24.
GeorgeOGhozlandSAzarMR (2007) CRF-CRF1
system activation mediates withdrawal-induced increases in nicotine
self-administration in nicotine-dependent rats. P
Natl Acad Sci USA104:
17198–17203.
25.
GeorgeTPO’MalleySS (2004) Current
pharmacological treatments for nicotine dependence.
Trends Pharmacol Sci25:
42–48.
GuillemKVouillacCAzarMR (2005) Monoamine
oxidase inhibition dramatically increases the motivation to self-administer
nicotine in rats. J Neurosci25:
8593–8600.
28.
GuillemKVouillacCAzarMR (2006) Monoamine
oxidase A rather than monoamine oxidase B inhibition increases nicotine
reinforcement in rats. Eur J Neurosci24:
3532–3540.
29.
GuillemKVouillacCKoobGFCadorMStinusL (2008) Monoamine oxidase
inhibition dramatically prolongs the duration of nicotine withdrawal-induced
place aversion. Biol Psychiat63:
158–163.
30.
HascoetMBourinMDhonnchadhaBA (2001) The mouse
light-dark paradigm: a review. Prog
Neuro-psychoph25:
141–166.
31.
HildebrandBENomikosGGHertelPSchilstromBSvenssonTH (1998) Reduced dopamine
output in the nucleus accumbens but not in the medial prefrontal cortex in
rats display a mecamylamine-precipitated nicotine withdrawal
syndrome. Brain Res779:
214–225.
32.
HolmKJSpencerCM (2000) Bupropion: a
review of its use in the management of smoking cessation.
Drugs59:
1007–1024.
33.
HughesJRHatsukamiDKSkoogK (1986) Physical
dependence on nicotine gum: a placebo substitution trial.
J Amer Med Assoc255:
3277–3279.
34.
IsolaRVogelsbergVWemlingerTANeffNHHadjiconstantinouM (1999) Nicotine
abstinence in the mouse. Brain Res850:
189–196.
35.
KellyGS (2001) Rhodiola
rosea: a possible plant adaptogen.
Altern Med Rev6:
293–302.
36.
KennyPJMarkouA (2001) Neurobiology of
the nicotine withdrawal syndrome. Pharmacol Biochem
Be70:
531–549.
37.
KoobGFLe MoalM (2001) Drug addiction,
dysregulation of reward, and allostasis.
Neuropsychopharmacology24:
97–129.
38.
KotaDMartinBRDamajMI (2008) Age-dependent
differences in nicotine reward and withdrawal in female
mice. Psychopharmacology (Berlin)198:
201–210.
39.
KurkinVAZapesochnayaGG (1986) Chemical
composition and pharmacological properties of Rhodiola
rosea. Chem Pharm J (Moscow)20:
1231–1244.
40.
LazarovaMBPetkovVDMarkovskaVLPetkovVVMosharrofA (1986) Effects of
meclofenoxate and Extr. Rhodiolae roseae L. on
electroconvulsive shock-impaired learning and memory in
rats. Method Find Exp Clin8:
547–552.
41.
LeeSYSongDKJangCG (2003) Effects of Coptis
japonica on morphine-induced conditioned place preference in
mice. Arch Pharm Res26:
540–544.
42.
LermanCAudrainJOrleansCT (1996)
Investigation of mechanisms linking depressed mood to
nicotine dependence. Addict Behav21:
9–19.
43.
LermanCRothDKaufmannV (2002) Mediating
mechanisms for the impact of bupropion in smoking cessation
treatment. Drug Alcohol Depen67:
219–223.
44.
LeroyCBragulatVBerlinI (2009) Cerebral
monoamine oxidase A inhibition in tobacco smokers confirmed with PET and
[11C]befloxatone. J Clin Psychopharm29:
86–88.
45.
LeventhalAMRamseySEBrownRALachanceHRKahlerCW (2008) Dimensions of
depressive symptoms and smoking cessation. Nicotine
Tob Res10:
507–517.
46.
LewisAMillerJHLeaRA (2007) Monoamine oxidase
and tobacco dependence. Neurotoxicology28:
182–195.
LinhPTKimYHHongSPJianJJKangJS (2000) Quantitative
determination of salidroside and tyrosol from the underground part of
Rhodiola rosea by high performance liquid
chromatography. Arch Pharm Res23:
349–352.
49.
MalinDH (2001) Nicotine
dependence: studies with a laboratory model.
Pharmacol Biochem Be70:
551–559.
MathersCDLoncarD (2006) Projections of
global mortality and burden of disease from 2002 to 2030.
PLoS Med3:
e442–e442.
52.
MattioliLFunariCPerfumiM (2009) Effects of
Rhodiola rosea L. extract on behavioural and
physiological alterations induced by chronic mild stress in female
rats. J Psychopharmacol23:
130–142.
53.
MattioliLPerfumiM (2007) Rhodiola
rosea L. extract reduces stress- and CRF-induced anorexia in
rats. J Psychopharmacol21:
742–750.
NestlerEJ (2001) Molecular
neurobiology of addiction. Am J Addict10:
201–217.
56.
PanagisGHildebrandBESvenssonTHNomikosGG (2000) Selective cfos
induction and decreased dopamine release in the central nucleus of amygdala
in rats displaying a mecamylamine-precipitated nicotine withdrawal
syndrome. Synapse35:
15–25.
57.
PanossianANikoyanNOhanyanN (2008) Comparative
study of Rhodiola preparations on behavioural despair of
rats. Phytomedicine15:
84–91.
58.
PerfumiMMattioliL (2007) Adaptogenic and
central nervous system effects of single doses of 3% rosavin and
1% salidroside Rhodiola rosea L. extract in
mice. Phytother Res21:
37–43.
59.
QuattrockiEBairdAYurgelun-ToddD (2000) Biological aspects
of the link between smoking and depression. Harvard
Rev Psychiat8:
99–110.
60.
RossSWilliamsD (2005) Bupropion: risks
and benefits. Expert Opin Drug Saf4:
995–1003.
61.
SahraeiHFatemiSMPashaei-RadSFaghih-MonzaviZSalimiSHKamalinegadM (2006) Effects of Papaver
rhoeas extract on the acquisition and expression of morphine-induced
conditioned place preference in mice. J
Ethnopharmacol103:
420–424.
62.
SaratikovAMarinaTFFisanovaLL (1978) Effect of golden
root extract on processes of serotonin synthesis in the CNS.
J Biol Sci6:
142–142.
63.
ShiffmanSDreslerCMRohayJM (2004) Successful
treatment with a nicotine lozenge of smokers with prior failure in
pharmacological therapy. Addiction99:
83–92.
64.
ShiffmanSShadelWGNiauraR (2003) Efficacy of
acute administration of nicotine gum in relief of cue-provoked cigarette
craving. Psychopharmacology (Berlin)166:
343–350.
65.
StanchevaSLMosharrofA (1987) Effect of the
extract of Rhodiola rosea L. on the content of the brain
biogenic monoamines. Medecine Physiologie Comptes
Rendus de l'Academie Bulgare des Sciences40:
85–87.
66.
SteadLFHughesJR (2000) Lobeline for
smoking cessation. Cochrane DB Syst Rev2:
CD000124–CD000124.
67.
StolermanIPJarvisMJ (1995) The scientific
case that nicotine is addictive.
Psychopharmacology117:
2–10.
68.
StolermanIPShoaibM (1991) The neurobiology
of tobacco addiction. Trends Pharmacol Sci12:
467–473.
69.
TalhoutROpperhuizenAVan AmsterdamJG (2007) Role of
acetaldehyde in tobacco smoke addiction. Eur
Neuropsychopharm17:
627–636.
70.
TapperARMcKinneySLNashmiR (2004) Nicotine
activation of alpha4* receptors: sufficient for reward, tolerance,
and sensitization. Science306:
1029–1032.
71.
ThompsonGHHunterDA (1998) Nicotine
replacement therapy. Ann Pharmacother32:
1067–1075.
72.
US Department of Health and Human
Sciences (1988) The health consequences of
smoking: nicotine addiction. A report of the Surgeon General
Maryland: Office on Smoking and Health.
73.
UzbayTI (2008) Hypericum
perforatum and substance dependence: a review.
Phytother Res22: 578–582
74.
Van DiermenDMarstonABravoJReistMCarruptPAHostettmannK (2009) Monoamine oxidase
inhibition by Rhodiola rosea L. roots.
J Ethnopharmacol122:
397–401.
75.
WangSYouXTWangFP (1992) HPLC determination
of salidroside in the roots of Rhodiola genus plants.
Yao Xue Xue Pao27:
849–852.
76.
WestRJRusselMAH (1985) Effects of
withdrawal from long term nicotine gum use. Psychol
Med15:
891–893.
WilkesS (2008) The use of
bupropion SR in cigarette smoking cessation. Intern
J Chron Obstruct Pulmon Dis3:
45–53.
79.
YoshikawaMShimadaHShimodaHMurakamiNYamaharaJMatsudaH (1996) Bioactive
constituents of Chinese natural medicines. II. Rhodiolae radix. (1).
Chemical structures and anti allergic activity of rhodiocyanosides A and B
from the underground part of Rhodiola quadrifida (Pal1.)
Fisch. et Mey. (Crassulaceae). Chem and Pharm Bull
(Tokyo)44:
2086–2091.
